Arai Y, Matsueda K, Inaba Y
Department of Diagnostic Radiology, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
Gan To Kagaku Ryoho. 2000 Dec;27(14):2193-200.
After randomized studies of hepatic arterial infusion chemotherapy (HAIC) versus systemic chemotherapy for liver metastases from colorectal cancer in the 1980s, the role of HAIC has been unclear and there is still no evidence to support it as the treatment of choice. The high local control, the differences in techniques between Japan and Western countries, the difficulty of detecting pre-treatment extra-hepatic metastases and the fact that HAIC does not control extra-hepatic lesions are the most important points in considering clinical trials of HAIC. Clinical studies on the combination of HAIC using 5-FU and systemic chemotherapy using CPT-11, and then randomized trial of systemic chemotherapy with/without HAIC is required in Japan to reveal the role of HAIC in the management of liver metastases from colorectal cancer. We should understand the importance of our role in this field.
在20世纪80年代对肝动脉灌注化疗（HAIC）与全身化疗治疗结直肠癌肝转移进行随机研究后，HAIC的作用一直不明确，目前仍没有证据支持其作为首选治疗方法。高局部控制率、日本与西方国家技术上的差异、检测治疗前肝外转移灶的困难以及HAIC不能控制肝外病变这一事实，是考虑HAIC临床试验时最重要的要点。在日本，需要开展关于使用5-氟尿嘧啶（5-FU）的HAIC与使用伊立替康（CPT-11）的全身化疗联合应用的临床研究，然后进行有/无HAIC的全身化疗随机试验，以揭示HAIC在结直肠癌肝转移治疗中的作用。我们应该明白我们在这一领域所起作用的重要性。
